Description de l'entreprise
Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.
Conseil d'administration & Conseil de surveillance
| PDG |
| Kevin Sayer |
| Conseil d'administration |
| Jereme Sylvain, Andrew K. Balo, Barry Regan, Chad Patterson, Don Abbey, Jake Leach, Paul Flynn, Sadie Stern, Shelly Selvaraj, Steven R. Pacelli, Sumi Shrishrimal |
| Conseil de surveillance |
| Kevin Sayer, Barbara E. Kahn, Bridgette Heller, Eric J. Topol, M.D., Jay Skyler, M.D., Karen Dahut, Kyle Malady, Mark Foletta, Nick Augustinos, Richard Collins, Steven R. Altman |
Données de l'entreprise
| Nom: |
Dexcom Inc. |
| Adresse: |
6340 Sequence Drive,San Diego, CA 92121, USA |
| Téléphone: |
+1-858-200-0200 |
| Fax: |
- |
| Courriel: |
-
|
| Internet: |
https://www.dexcom.com/ |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
- |
Relations avec les investisseurs
| Nom: |
Steve Pacelli |
| Téléphone IR: |
- |
| IR-Fax: |
- |
| E-mail IR: |
spacelli@dexcom.com
|
